Moderna stock exploded 177% on Wednesday, August 19, after Moderna and Merck reported a landmark Phase 3 victory for their personalized mRNA melanoma treatment—only two weeks after Moderna secured FDA approval for its first flu vaccine. The extraordinary rally also put a spotlight back on President Donald Trump’s disclosed Moderna trades: filings reported earlier this summer showed purchases of MRNA shares in March, followed by a smaller partial sale in May.
For investors, the bigger story goes far beyond one politically eye-catching portfolio position. Moderna has suddenly received two powerful validations of its mRNA platform—FDA approval in influenza and successful Phase 3 oncology data—potentially transforming a company Wall Street had increasingly treated as a fading COVID-era vaccine play.
MRNA Stock Nearly Triples on a Historic Cancer-Vaccine Win
Moderna shares surged 177% on August 19, their largest one-day gain since the company went public, according to MarketWatch and the Financial Times. The FT said the rally added roughly $44 billion to Moderna’s market capitalization, while Merck gained sharply as well.
The catalyst was INTerpath-001, a Phase 3 study testing Moderna’s intismeran autogene alongside Merck’s blockbuster cancer drug Keytruda in patients with completely resected stage IIB-IV melanoma.
The trial enrolled 1,137 patients and compared the combination against Keytruda alone. Moderna and Merck said the therapy produced statistically significant and clinically meaningful improvement in recurrence-free survival, the study’s primary endpoint, while also meeting a key secondary endpoint measuring distant metastasis-free survival.
Related articles
No new safety signals were reported.
That combination of efficacy and tolerability is exactly what investors had been waiting for.
It is the first successful Phase 3 readout for an individualized mRNA-based cancer therapy, potentially proving that the technology behind Moderna’s COVID vaccine can generate commercially meaningful medicines far beyond infectious disease.
Why Trump’s Moderna Investment Is Suddenly Back in Focus
The explosive MRNA stock rally has revived interest in President Trump’s previously disclosed trades in Moderna.
According to an analysis by Quiver Quantitative of public transaction filings, Trump’s investment accounts bought between $15,001 and $50,000 of Moderna shares on March 2 and another $1,001 to $15,000 on March 17. A subsequent filing showed a sale valued between $1,001 and $15,000 on May 18.
The exact number of shares and the precise profit cannot be calculated from those disclosures because federal financial reports generally disclose transaction values within ranges rather than exact dollar amounts.
There is also no evidence in the cited disclosures that Trump personally selected or directed these trades. Trump has previously said independent managers handle his financial assets, and Reuters reported in July that his disclosed portfolios had expanded substantially while being managed separately from his day-to-day involvement.
That distinction is important.
The market relevance is not that the president somehow predicted the clinical outcome. It is that two Moderna investments disclosed earlier this year happened before two exceptionally favorable catalysts—and MRNA stock has now produced one of the most dramatic rallies in S&P 500 history.
First Dose: FDA Approves Moderna’s mFLUSIVA
The cancer-vaccine breakthrough was not Moderna’s only major August victory.
On August 5, the U.S. Food and Drug Administration approved mFLUSIVA, Moderna’s mRNA-based seasonal influenza vaccine for adults aged 50 and older.
It became Moderna’s fifth approved product and the first mRNA flu vaccine cleared by the FDA. Moderna expects it to become available to eligible U.S. adults during the 2026-2027 respiratory-virus season.
That approval was especially significant because the regulatory path had been anything but smooth.
Earlier in 2026, the FDA initially refused to accept Moderna’s application before reversing course and agreeing to review it. The eventual approval therefore removed an important regulatory overhang at a time when investors had been questioning whether shifting U.S. vaccine policy would undermine Moderna’s pipeline.
For Moderna bulls, mFLUSIVA was the first dose of good news.
The melanoma trial delivered the second—and considerably larger—shock.
Second Dose: Cancer Data Changes the MRNA Stock Story
Before Wednesday, Moderna’s valuation debate largely revolved around a difficult question: could the company replace disappearing COVID-era revenue before its cash pile was depleted?
The Phase 3 melanoma success changes that conversation.
Intismeran is not a conventional preventive vaccine. It is an individualized cancer therapy manufactured based on mutations identified in each patient’s tumor. The synthetic mRNA encodes as many as 34 tumor-specific neoantigens designed to train the patient’s immune system to recognize and attack cancer cells.
Earlier Phase 2 data had already generated optimism.
At five years of follow-up, Moderna and Merck reported in June that intismeran plus Keytruda reduced the risk of recurrence or death by 49% compared with Keytruda alone and reduced the risk of distant metastasis or death by 59%.
Phase 3 was the crucial test.
Passing it provides substantially stronger evidence that the efficacy observed in the smaller trial can translate into a larger patient population.
That validation explains why Wall Street did not treat Wednesday’s announcement like an ordinary biotech trial update.
Investors repriced the entire Moderna platform.
Moderna’s Financial Problem Has Not Disappeared
The rally does not erase Moderna’s financial challenges.
In its July 31 second-quarter results, Moderna reported only about $0.1 billion in revenue, a GAAP net loss of approximately $0.8 billion, and a loss of $1.97 per share. Management nevertheless maintained its expectation for up to 10% revenue growth in 2026 and raised its forecast for year-end cash to between $4.7 billion and $5.2 billion after additional cost reductions.
Those numbers illustrate why successful pipeline development matters so much.
Moderna built an enormous cash reserve during the pandemic, but collapsing COVID vaccine sales transformed the investment case. Without profitable new products, continued R&D spending would steadily consume that capital.
The company has already encountered pipeline setbacks.
Its Phase 3 norovirus vaccine did not meet the statistical threshold for early success at an interim analysis, forcing Moderna to prepare an additional enrollment cohort.
Biotech development remains binary.
One spectacular clinical success does not eliminate the possibility of expensive failures elsewhere.
How Big Could Moderna’s Cancer Opportunity Become?
The melanoma indication alone could become a multibillion-dollar commercial opportunity if regulators approve intismeran.
Reuters reported analyst estimates ranging into the billions of dollars in annual melanoma sales over the coming decade, although precise forecasts vary considerably. Importantly, Moderna and Merck share costs and profits from the program, meaning headline sales estimates should not be treated as revenue belonging entirely to Moderna.
But melanoma may only be the opening act.
Moderna and Merck are studying intismeran across multiple tumor types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma. Their clinical program includes numerous Phase 2 and Phase 3 studies.
That is where Wednesday’s valuation surge becomes easier to understand.
Investors are not simply assigning value to one melanoma medicine. They are increasingly pricing in the possibility that Moderna has developed a reusable platform for personalized cancer treatment.
Reuters Breakingviews noted that Moderna’s enormous increase in market value effectively implies expectations for success beyond melanoma. If follow-on trials fail, that optimism could unwind quickly.
MRNA Stock Forecast: The Market Is Pricing in Much More Than Melanoma
A 177% one-day gain inevitably creates valuation risk.
Before Wednesday’s announcement, Moderna was still fighting to prove it could build a sustainable post-COVID business. One trading session later, investors were assigning tens of billions of dollars of additional value to the company.
That is an enormous leap in expectations.
Reuters reported that short interest represented roughly 13.5% of Moderna’s freely traded shares before the rally, meaning short covering likely amplified the move. Bearish traders potentially suffered billions of dollars in mark-to-market losses as MRNA stock ripped higher.
Investors therefore need to separate three effects: genuine fundamental repricing, speculative momentum and forced short buying.
The first appears justified by the Phase 3 result.
The magnitude of the second and third is much harder to quantify.
Moderna and Merck have not yet released the complete Phase 3 dataset. Investors still need the actual hazard ratios, detailed subgroup results, longer-term safety information and eventually overall-survival data before accurately estimating the therapy’s commercial potential.
Reuters reported that analysts were enthusiastic but cautioned that those details remain important.
What Investors Should Watch Next
The immediate catalyst is the full INTerpath-001 presentation. Moderna and Merck intend to present detailed results at an upcoming international medical meeting and discuss the data with regulators. A potential U.S. approval process could then become one of the biggest biotech stories of 2027.
Investors should also track the rollout of mFLUSIVA, Moderna’s quarterly cash burn, additional intismeran trials and any updates on manufacturing capacity for personalized cancer treatments.
MRNA stock has already moved as though Moderna’s post-COVID reinvention has succeeded.
Now the company must prove that Wednesday’s stunning Phase 3 win can become actual regulatory approvals, commercial sales and recurring profits.
Trump’s disclosed Moderna position may have received a remarkable double dose of good fortune—but after a 177% surge, the next dose of data could matter even more.
